12 results about "FGF19" patented technology

This invention relates to the field of cosmetics, and more particularly to active oligopeptides and their application in the preparation of anti-aging products. This invention provides an active oligopeptide with anti-aging activity, the amino acid sequence of which is shown in SEQ ID NO:1 and / or SEQ ID NO:4. This invention also provides an active oligopeptide (β1 and β1c) designed based on computational structural biology, targeting the β-Klotho FGF19 / / FGF21 and receptor-binding arm (RBA) region, and optimized for physicochemical properties, for use in skin anti-aging.

The application provides a macrophage-targeted FGF19 sustained-release delivery system, a preparation method and an application. The system comprises FGF19-loaded macrophage membrane-derived nanoparticles and a temperature-sensitive hydrogel embedding the nanoparticles. The temperature-sensitive hydrogel is made of chitosan, poloxamer and beta-glycerophosphate sodium. The size of the macrophage membrane-derived nanoparticles is 300-800 nm. The system is an injectable liquid at 0-10 DEG C and forms a gel at 20-37 DEG C, achieving sustained release of FGF19 and drug-loaded vesicles. The system can promote re-epithelialization, collagen deposition, angiogenesis and M2 macrophage infiltration of a wound surface and is used for preparing a medicine or a dressing for promoting skin wound repair.

The present invention provides nucleic acid molecules for modulating the level or amount of mRNA of FGF19. In particular, the present invention provides delivery of a primary microRNA to form a precursor after in vivo processing, as well as a microRNA, for in vivo inhibition of expression of mRNA of FGF19. The invention also provides a delivery system of the nucleic acid molecule, comprising a carrier, an exosome and a cell, and a pharmaceutical composition containing the same. The invention also provides the use of the nucleic acid molecule and delivery system in disease treatment and drug preparation, in particular methods and drugs for cancer.

The invention discloses creation of engineered escherichia coli expressing and secreting FGF19 and application of the engineered escherichia coli in improvement of colitis, and belongs to the technical field of biology. According to the engineering bacterium, E.coli Nissle 1917 is taken as a chassis bacterium, and a section of 1020 bp nucleotide sequence expression cassette comprising an anaerobic promoter (PfnrS), a ribosome binding site (RBS), an escherichia coli ompA signal peptide, a human FGF19 CDS and an rrnB1 terminator sequence is inserted on an exo / cea site of a genome of the engineering bacterium through a CRISPR-Cas9 gene editing technology. The growth curve of the strain is not obviously different from that of a wild strain, the FGF19 gene and protein can be expressed under an anaerobic culture condition, and the concentration of the FGF19 secreted into a culture medium in a logarithmic phase (6 hours) reaches 8 ng / mL. By oral administration of the engineering bacterium EcN FGF19-01 or the microcapsule wrapping the engineering bacterium EcN FGF19-01, the weight of mice with colitis can be remarkably improved, and the diarrhea index and intestinal mucosa injury can be reduced. The engineering bacterium EcN FGF19-01 disclosed by the invention is used for preparing a pharmaceutical composition, a health care product and a feed additive for relieving colitis, and has a very wide application prospect.

The invention relates to FGF19 mutant protein and application thereof. Compared with the FGF19, the mutant protein disclosed by the invention has the advantages that on the premise of keeping the functions of up-regulating high-density lipoprotein content and down-regulating blood sugar, triglyceride, bile acid and total cholesterol of the FGF19, the side effects of liver function damage, liver cell proliferation promotion and the like caused by up-regulating low-density lipoprotein, up-regulating total bilirubin and direct bilirubin by the FGF19 are relieved. In addition, consistent with FGF19, the mutant protein provided by the invention can improve liver cell lesion.

The present invention provides an anti-FGF-19 antibody and an antigen-binding fragment thereof that selectively targets the N-terminus of fibroblast growth factor 19 (FGF19). Also provided are compositions and uses of the antibodies, and methods for treating diseases or conditions caused by or associated with abnormal FGF19-FGFR4 signaling, such as cancer, by administering the anti-FGF-19 antibodies.

This invention relates to FGF19 mutant protein and its applications. Compared with FGF19, the mutant protein of this invention retains the functions of FGF19 in upregulating high-density lipoprotein levels and downregulating blood glucose, triglycerides, bile acids, and total cholesterol, while alleviating the side effects of FGF19 such as liver damage and hepatocyte proliferation caused by upregulating low-density lipoprotein, total bilirubin, and direct bilirubin. Furthermore, consistent with FGF19, the mutant protein of this invention can improve hepatocellular lesions.

The invention provides an application of an HOXA3 gene as a target spot in screening and treating drugs for hepatocellular carcinoma. Through single-cell multi-omics analysis, the HOXA3 is found to be remarkably and highly expressed in liver cancer tissues and is closely related to poor prognosis of patients. Mechanism research shows that HOXA3 promotes tumor proliferation and metastasis through transcriptional up-regulation of YAP1 and RHOA, and an FGF19-FGFR4 / beta-catenin signal channel positively regulates the expression of HOXA3. The invention verifies that the combined application of the YAP1 inhibitor Verteporfin and the RHOA inhibitor Rhosin can significantly inhibit the HOXA3-mediated liver cancer progress, in-vivo experiments show that the tumor volume is reduced by 68%, the lung metastasis inhibition rate reaches 83%, and an effective treatment strategy is provided for HOXA3 positive hepatocellular carcinoma.

Provided are anti-FGF19 antibodies that selectively target N-terminus of fibroblast growth factor 19 (FGF19) and antigen-binding fragments thereof, as well as uses of said antibodies in treating a disease or disorder caused by or related to abnormal FGF19-FGFR4 signaling, e.g., cancer.

The current disclosure provides for improved methods of treating patients who have received immune checkpoint inhibitor (ICI) therapy and based on the finding that biomarkers can predict whether a subject experiencing adverse symptoms and undergoing ICI therapy is developing an irAE due to the ICI therapy or due to a pathology not directly related to the ICI therapy. The methods include a method for evaluating a subject comprising measuring the level of one or more biomarkers in a biological sample from the subject, wherein the biomarker(s) are one or more of IL5, CD274, TNFSF4, FAS, IL20, TSLP, TNFSF15, CCL1, IL6, TNF, CLEC4A, NCR1, FGF19, IL5RA, MUC16, CCL3, VCAM1, EPO, IFNL1, MMP3, IL9, IL16, IL36A, FLT1, IL18, IL12RB1, KITLG, LTF, CCL18, LCN2, CXCL13, S100A8, CXCL9, CD79A, CCR7, CXCL1, C3, TREM1, IL7R, CD19, LTB, MS4A1, SAA1, CXCL10, C1QB, TNFRSF17, CTLA4, CXCL6, CD27, CD38, CXCL11, CD163, FCGR3A, ITGAX, CD7, C1QA, RUNX3, SLAMF7, IRF4, SELL, ZAP70, CD48, SIGLEC1, PDCD1, IL2RB, JAK3, CTSS, CSF2RB, IL2RG, ISG20, EBI3, C2, ITGAL, CCR5, IDO1, LCP1, CD5, CD6, SH2D1A, CYBB, CCL5, IL10RA, VEGFC, IL13RA2, IL36G, MMP9, EGF, CTF1, CHI3L1, IL1R1, TNFRSF8, SPP1, IL15RA, TNFRSF1B, TNFRSF18, TNFRSF1A, CX3CL1, CD40, IL17A, TNFRSF14, CXADR, TNFRSF9, TNFRSF11A, TNFSF11, IL2RA, MDK, IL18BP, LTBR, SLURP1, CSF1, and IL33.

The application discloses a kind of biomimetic polypeptide FGF19-1 based on protein FGF19 and application thereof.The present application utilizes endogenous protein FGF19 which can specifically bind to fibroblast growth factor receptor FGFR4, designs related biomimetic polypeptide, simultaneously combines optical imaging technology and coupling fluorescent dye technology, so that it can be applied to early accurate screening and intraoperative accurate navigation of hepatocellular carcinoma.The amino acid sequence of FGF19-1 disclosed in the present application is: Ile-Met-Pro-Asn-Glu-Tyr-Asn-Val-Lys-Val-Asn-Tyr-Glu-Asn-Pro-Met-Ile, which can specifically bind to tumor cells with high expression of FGFR4, and after coupling with fluorescent dye, in vivo optical imaging and results confirm that it has excellent imaging results for hepatocellular carcinoma.

The invention relates to the field of biological medicine, and discloses a biliary atresia preoperative prognosis evaluation product and method based on serum FGF19. The invention provides a metabolite combination for biliary atresia preoperative prognosis evaluation, the metabolite combination comprises FGF19, GGT, DBIL and ALB, a formula for evaluating the prognosis risk according to the concentration of the metabolite is provided, and the risk can be graded according to the grading result of the formula. According to the scheme provided by the invention, more theoretical bases are provided for selection of treatment schemes for children with biliary atresia in the future, and a doctor can be helped to judge whether the children still have the possibility of benefiting from the Kuzhi surgery before the Kuzhi surgery or directly perform liver transplantation so as to avoid unnecessary operative wounds.